BACKGROUND: The extended use of antiretroviral drugs among human immunodeficiency virus (HIV)-seropositive individuals underscores the need for a comprehensive evaluation of therapy-associated clinical symptoms. METHODS: Beginning in April 2000, 364 HIV-seronegative and 1256 HIV-seropositive women enrolled in a multicenter cohort study reported clinical symptoms that included abdominal pain, diarrhea, anorexia, nausea and/or vomiting, myalgias, fatigue, fever, body fat redistribution, dizziness, headaches, paresthesias, xerostomia, nephrolithiasis, and rash. We examined the prevalence of symptoms with respect to HIV infection and the use of highly active antiretroviral therapy (HAART), using data-correlation models. RESULTS: In the 6 months before a study visit, 49% of HIV-seronegative women, 67% of HIV-seropositive women not receiving therapy, and 69% of HIV-seropositive women receiving HAART reported any clinical symptom. The odds ratios (ORs) for reporting any symptom were 1.4 (95% confidence interval [CI], 1.1-1.8) for women who changed HAART regimens and 0.9 (95% CI, 0.7-1.1) for women reporting stable HAART use, compared with those reporting no therapy use. Significant findings (P<.05) for particular symptoms were an increased odds of diarrhea, nausea and/or vomiting, body fat redistribution, myalgias, and paresthesias, when data for women who changed HAART regimens were compared with those for women not receiving therapy. The OR for reporting any symptom was 1.5 (95% CI, 1.2-1.9) for women who switched HAART regimens and 1.6 (95% CI, 1.3-1.9) for women who discontinued HAART, compared with those reporting stable HAART use. CONCLUSIONS: Our findings confirm the high prevalence of clinical symptoms among HIV-seropositive women who changed HAART regimens. The high prevalence of symptoms among HIV-seronegative women and HIV-seropositive women not receiving therapy demonstrates that caution should be used when attributing the occurrence of symptoms entirely to HAART.
BACKGROUND: The extended use of antiretroviral drugs among human immunodeficiency virus (HIV)-seropositive individuals underscores the need for a comprehensive evaluation of therapy-associated clinical symptoms. METHODS: Beginning in April 2000, 364 HIV-seronegative and 1256 HIV-seropositivewomen enrolled in a multicenter cohort study reported clinical symptoms that included abdominal pain, diarrhea, anorexia, nausea and/or vomiting, myalgias, fatigue, fever, body fat redistribution, dizziness, headaches, paresthesias, xerostomia, nephrolithiasis, and rash. We examined the prevalence of symptoms with respect to HIV infection and the use of highly active antiretroviral therapy (HAART), using data-correlation models. RESULTS: In the 6 months before a study visit, 49% of HIV-seronegative women, 67% of HIV-seropositivewomen not receiving therapy, and 69% of HIV-seropositivewomen receiving HAART reported any clinical symptom. The odds ratios (ORs) for reporting any symptom were 1.4 (95% confidence interval [CI], 1.1-1.8) for women who changed HAART regimens and 0.9 (95% CI, 0.7-1.1) for women reporting stable HAART use, compared with those reporting no therapy use. Significant findings (P<.05) for particular symptoms were an increased odds of diarrhea, nausea and/or vomiting, body fat redistribution, myalgias, and paresthesias, when data for women who changed HAART regimens were compared with those for women not receiving therapy. The OR for reporting any symptom was 1.5 (95% CI, 1.2-1.9) for women who switched HAART regimens and 1.6 (95% CI, 1.3-1.9) for women who discontinued HAART, compared with those reporting stable HAART use. CONCLUSIONS: Our findings confirm the high prevalence of clinical symptoms among HIV-seropositivewomen who changed HAART regimens. The high prevalence of symptoms among HIV-seronegative women and HIV-seropositivewomen not receiving therapy demonstrates that caution should be used when attributing the occurrence of symptoms entirely to HAART.
Authors: J Fellay; K Boubaker; B Ledergerber; E Bernasconi; H Furrer; M Battegay; B Hirschel; P Vernazza; P Francioli; G Greub; M Flepp; A Telenti Journal: Lancet Date: 2001-10-20 Impact factor: 79.321
Authors: L Ahdieh Grant; M J Silverberg; H Palacio; H Minkoff; K Anastos; M A Young; M Nowicki; A Kovacs; M Cohen; A Muñoz Journal: AIDS Date: 2001-11-09 Impact factor: 4.177
Authors: Jeanne P Dieleman; Marielle Jambroes; Inge C Gyssens; Miriam C J M Sturkenboom; Bruno H Ch Stricker; Wilhelmina M C Mulder; Frank de Wolf; Gerrit-Jan Weverling; Joep M A Lange; Peter Reiss; Kees Brinkman Journal: AIDS Date: 2002-03-29 Impact factor: 4.177
Authors: P Bonfanti; L Valsecchi; F Parazzini; S Carradori; L Pusterla; P Fortuna; L Timillero; F Alessi; G Ghiselli; A Gabbuti; E Di Cintio; C Martinelli; I Faggion; S Landonio; T Quirino Journal: J Acquir Immune Defic Syndr Date: 2000-03-01 Impact factor: 3.731
Authors: Judith A Cook; Mardge H Cohen; Dennis Grey; Lynn Kirstein; Jane Burke; Kathryn Anastos; Herminia Palacio; Jean Richardson; Tracey E Wilson; Mary Young Journal: Am J Public Health Date: 2002-01 Impact factor: 9.308
Authors: Giovanni Schifitto; Lijuan Deng; Tzu-Min Yeh; Scott R Evans; Thomas Ernst; Jianhui Zhong; David Clifford Journal: J Neurovirol Date: 2010-12-23 Impact factor: 2.643
Authors: Michael J Silverberg; Lisa P Jacobson; Audrey L French; Mallory D Witt; Stephen J Gange Journal: J Pain Symptom Manage Date: 2009-03-28 Impact factor: 3.612
Authors: Jessica S Merlin; Melonie Walcott; Robert Kerns; Matthew J Bair; Kathryn L Burgio; Janet M Turan Journal: Pain Med Date: 2015-02-03 Impact factor: 3.750
Authors: Sean N Halpin; Edwin Clayton Carruth; Ramona P Rai; E Jennifer Edelman; David A Fiellin; Cynthia Gibert; Kirsha S Gordon; Wei Huang; Amy Justice; Vincent C Marconi; David Rimland; Molly M Perkins Journal: AIDS Behav Date: 2018-03
Authors: Michael J Silverberg; Gary Thomas Ray; Kathleen Saunders; Carolyn M Rutter; Cynthia I Campbell; Joseph O Merrill; Mark D Sullivan; Caleb J Banta-Green; Michael Von Korff; Constance Weisner Journal: Clin J Pain Date: 2012-01 Impact factor: 3.442
Authors: Jessica S Merlin; Liyi Cen; Amy Praestgaard; Michelle Turner; Aura Obando; Craig Alpert; Sophie Woolston; David Casarett; Jay Kostman; Robert Gross; Ian Frank Journal: J Pain Symptom Manage Date: 2011-11-23 Impact factor: 3.612
Authors: E Jennifer Edelman; Kirsha Gordon; Maria C Rodriguez-Barradas; Amy C Justice Journal: AIDS Patient Care STDS Date: 2012-05-21 Impact factor: 5.078
Authors: David B Hanna; Nancy A Hessol; Elizabeth T Golub; Jennifer M Cocohoba; Mardge H Cohen; Alexandra M Levine; Tracey E Wilson; Mary Young; Kathryn Anastos; Robert C Kaplan Journal: J Acquir Immune Defic Syndr Date: 2014-04-15 Impact factor: 3.731
Authors: Julie Womack; Susan Richman; Phyllis C Tien; Margaret Grey; Ann Williams Journal: J Midwifery Womens Health Date: 2008 Jul-Aug Impact factor: 2.388